WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at the 2014 Baird Health Care Conference. The presentation is at the New York Palace on Sept. 4, 2014, at 9:40 a.m. ET in New York, NY.
A live webcast of the presentation can be accessed by visiting “Events & Presentations” in the Investors and Media section on the Company’s website at www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference.
In addition, Dicerna will be attending the FBR Inaugural Healthcare Conference on Sept. 3, 2014. The conference brings together investors and senior management from more than 40 companies for a series of one-on-one meetings and will be held in Boston at the Four Seasons hotel.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.
